Single doses of cefazolin, 500 mg intramuscularly and 1 g intravenously, were administered to 16 patients having lung pathology who were scheduled for thoracic fluid aspiration. Pleural fluid and serum samples were taken at intervals of 30 to 240 min for determination of cefazolin levels. The levels obtained were variable; however, the levels of cefazolin in pleural fluid generally exceeded the reported minimal inhibitory concentration values for Staphylococcus pneumoniae and Staphylococcus, and group A beta-hemolytic streptococcus. In addition, the pleural fluid levels exceeded the minimal inhibitory concentration for cefazolin against most of the Klebsiella and Haemophilus influenzae strains. These data show that cefazolin, despite its comparative high protein binding, produces levels in the pleural fluid capable of inhibiting the organisms commonly found in respiratory tract infections.
Cephalosporins such as cefazolin and cephalothin are used effectively to treat infections of the respiratory tract caused by Streptococcus pneumoniae, Klebsiella species, Staphylococcus aureus, group A beta-hemolytic streptococcus, and Haemophilus influenzae. Cefazolin and cephalothin have a similar broad spectrum of activity; however, cefazolin produces higher and longer-lasting blood levels than does cephalothin. On the other hand, cefazolin is more highly protein bound than cephalothin -86% compared with 65% -and some investigators have questioned whether this might be a disadvantage to the use of cefazolin in that it might not penetrate the tissue in adequate doses (5) . The clinical significance of protein binding, if any, is highly controversial, particularly as in the case of cefazolin, when the antibiotic has been found to be effective in eradicating the causative organisms and producing the desired clinical response in patients with respiratory tract infections (2, 7, 8, 11 All standards were prepared in pooled human serum for serum and pleural fluid assays. All samples of serum or pleural fluid that required diluting prior to assay were diluted with pooled human serum by using the same lot in which the standards had been prepared. Each of the four to five standards were replicated 12 to 18 times, whereas each sample was replicated 12 times, i.e., 12 to 18 disks per standard concentration with three disks per plate. Although the protein content and pH of the pleural fluid were not known, the samples were evaluated versus a serum curve; therefore, the cefazolin concentration estimates are conservative rather than optimistic, assuming that the serum protein (albumin) content of pleural fluid is less than that of serum, especially with regard to serum albumin.
RESULTS AND DISCUSSION
A total of 18 samples of serum and pleural fluid were obtained. Table 2 were reported by various investigators by a different methodology; however, there is general agreement among investigators (1, 3, 9, 10) . Cephalothin also penetrates the pleural fluid in therapeutic levels (4, 6) . Unfortunately, it is not possible to make direct comparisons between these data and ours, since cephalothin was administered in a dosage of 12 g/day, and the serum and pleural fluid samples were taken after 24 or 48 h ofdosing. The cephalothin levels reported are of interest, however, in that they show great variability, as did the cefazolin levels. The level of cephalothin in the pleural fluid of one patient, after 2 days of a 12-g/day dosing schedule, was 5.4 ,ug/ml; the pleural fluid level of cephalothin in tie other patient 2 h after dose 11 was 40.8 ,g/ml, and it was 70.6 ug/ml 1 h after dose 24. As was mentioned, cefazolin has been used successfully to treat respiratory tract infections. In our previous study, cefazolin produced satisfactory clinical and bacteriological responses in 22 out of 23 patients having infections such as pneumonia or bronchitis associated with malignant disease; beta-hemolytic streptococcus and S. pneumoniae were the most frequently isolated organisms (2). Turck et al. reported that 64 of his 68 patients with pneumonia due to S. pneumoniae improved on cefazolin (11). Madhavan et al. obtained good results in all 24 patients having pneumonia caused by S. pneumoniae, Staphylococcus, or H. influenzae (7) . Similarly, Mogabgab obtained good results in 54 patients having pneumonococcal pneumonia or pneumonococcal bronchitis; all had severe pulmonary or other diseases (8) . It would seem, therefore, that any clinical significance of its protein-binding properties is highly questionable, since cefazolin penetrates the pleural fluid in therapeutic levels and produces the desired clinical and bacteriological responses in pneumonia, bronchitis, and other pulmonary tract infections caused by cephalosporin-susceptible organisms.
